NYSE:ABTMedical Equipment
Abbott’s US$20b Bond Bet Recasts Growth Story In Oncology Diagnostics
Abbott Laboratories (NYSE:ABT) is acquiring cancer diagnostics company Exact Sciences in a deal financed by a US$20b bond sale.
The transaction marks Abbott's entry into oncology diagnostics, expanding its presence in higher growth testing and screening markets.
The large bond issuance is set to reshape Abbott's capital structure and raises fresh questions about risk, return and balance sheet flexibility.
Abbott Laboratories, trading at around US$114.76, is moving beyond its traditional...